Bright Peak Therapeutics, Ajinomoto Collaborates to Create Novel Immunocytokines
Bright Peak Therapeutics has announced a research and licensing collaboration with Ajinomoto to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation technology, for the development of Bright Peak Immunocytokines.
Bright Peak leverages a novel ligation technology to chemically synthesize therapeutic cytokines by ligating together customized peptide segments. This platform offers unique flexibility to tune and augment cytokine biology through affinity modification and orthogonal, site-specific conjugation, respectively.
Under the terms and condit...
